EN DE
Watch BridgeBio Oncology Therapeutics, Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

BridgeBio Oncology Therapeutics, Inc. (BBOT) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of BridgeBio Oncology Therapeutics, Inc. stock $1.89, price $1.81, upside +4.4%, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US1079241022

BO BridgeBio Oncology Therapeutics, Inc. logo Thin data Nov 20, 2026

BridgeBio Oncology Therapeutics, Inc.

BBOT · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Costs just 3.4 times its yearly profit. 
Fair value $1.89 · Fairly valued 
Mixed vs. peers (3/6) 
Insiders sold $3,628 (6M) 
Quality 33/100 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
EstimateData corrected by AI research
Watch BridgeBio Oncology Therapeutics, Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.73 $1.81 Fair Value $1.89 Aug 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.

How to read this chart

15‑month range $1.81 – $13.73 · fair‑value band $1.42 – $2.36 · the $1.81 price screens below the $1.89 fair value. As of Nov 20, 2026.

Follow BridgeBio Oncology Therapeutics in your weekly email

Every Wednesday you see whether BridgeBio Oncology Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.

Show moreShow less

The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.

The company was incorporated in 2016 is headquartered in South San Francisco, California.

Stock analysis

BridgeBio Oncology Therapeutics, Inc. (BBOT) currently trades at $1.81, while our estimate is $1.89, so the stock looks roughly fairly valued today (gap 4.2%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.42 (bear) to $2.36 (bull), the price of $1.81 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

BridgeBio Oncology Therapeutics, Inc. reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was −$134M in FY2025.

Key figures

Market cap $189M Micro · P/E ratio 3.4 · EPS (TTM) $0.53 · Return on equity −46.4% · Return on assets (EBIT) −3,913% (5-year average) · Free cash flow −$115M · Net cash $371M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 87% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 4%, BBOT screens cheaper than that median.

Fair Value

Bear $1.42 Fair Value $1.89 Bull $2.36
Price $1.81 · Upside +4.4%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $3,628 and none bought.

  • SalePedro BeltranPresident and CEO, Director1,870 shares at $1.84$3,443Nov 18, 202610b5-1 plan
  • SaleMarc CoboPrincipal Accounting Officer78 shares at $2.37$185Nov 13, 202610b5-1 plan

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BBOT, get fair value alerts →

Compare BridgeBio Oncology Therapeutics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside +4.4% · Top 25%
Profitability
Return on assets −29.9% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 3.4× · Cheapest 25%
P/B 0.46× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 5
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs BBOT
Vertex Pharmaceuticals Incorporated VRTX $515.02 $587.62 +14% vs BBOT
Samsung Biologics Co 207940 ₩1,355,000 ₩1,512,500 +12% vs BBOT
argenx SE ARGX $925.70 $908.40 −2% vs BBOT
CSL Limited CSL A$197.29 A$188.80 −4% vs BBOT
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs BBOT
Moderna, Inc MRNA $195.00 $122.98 −37% vs BBOT
Revolution Medicines, Inc RVMD $161.20 $83.12 −48% vs BBOT
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs BBOT
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs BBOT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BridgeBio Oncology Therapeutics, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BridgeBio Oncology Therapeutics, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/BBOT

Frequently asked questions

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) overvalued or undervalued?
As of Nov 20, 2026, our estimate of fair value is $1.89 versus a price of $1.81, about +4% upside (fairly valued).
What is the fair value of BBOT?
Our estimate for BridgeBio Oncology Therapeutics, Inc. is $1.89 (as of Nov 20, 2026), built from audited fundamentals. The current price: $1.81.
What is the quality score of BBOT?
BridgeBio Oncology Therapeutics, Inc. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BridgeBio Oncology Therapeutics, Inc. (BBOT)?
We do not set a price target; the yardstick is our estimate of $1.89 (as of Nov 20, 2026). Cautious scenario $1.42, optimistic scenario $2.36. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the BridgeBio Oncology Therapeutics, Inc. stock forecast for 2026?
Our estimate puts fair value at $1.89, about +4% upside versus a price of $1.81 (fairly valued). Cautious scenario $1.42, optimistic scenario $2.36. The calculation is refreshed regularly with new filings.
What is the intrinsic value of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BridgeBio Oncology Therapeutics, Inc. it is $1.89 per share (as of Nov 20, 2026), against a price of $1.81.
Is BridgeBio Oncology Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of Nov 20, 2026, BBOT trades below its calculated fair value: price $1.81, fair value $1.89, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BBOT?
No. The price is what the market pays today ($1.81); the fair value is what the company's own numbers justify ($1.89). For BridgeBio Oncology Therapeutics, Inc. the two are $0.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is BridgeBio Oncology Therapeutics, Inc. worth?
The market values BridgeBio Oncology Therapeutics, Inc. at about $189M (market capitalisation, as of Nov 20, 2026). Per share that is $1.81; our models calculate a fair value of $1.89 per share.
What do the bullish and bearish scenarios say about BBOT?
Our models span a range for BridgeBio Oncology Therapeutics, Inc.: cautious scenario $1.42, base $1.89, optimistic $2.36 per share (as of Nov 20, 2026, price $1.81). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BBOT?
BridgeBio Oncology Therapeutics, Inc. trades at a price-to-earnings ratio of 3.4 (as of Nov 20, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.89 is built from several models across several years. Other multiples: P/B 0.5.
How solid is the balance sheet of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
Balance-sheet figures for BridgeBio Oncology Therapeutics, Inc. (as of Nov 20, 2026): return on equity −46.4%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is BBOT from its 52-week high?
BridgeBio Oncology Therapeutics, Inc. trades at $1.81, about 87% below its 52-week high of $13.69 and at the low of $1.81 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $1.89 is for.
Which stocks are comparable to BridgeBio Oncology Therapeutics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BridgeBio Oncology Therapeutics, Inc. stock attractive at the current price?
The data as of Nov 20, 2026: price $1.81, calculated fair value $1.89 (+4%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 9.6% above its aggregate fair value. BridgeBio Oncology Therapeutics, Inc. currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
The closing price on Nov 20, 2026 was $1.81. Our estimate is $1.89, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BridgeBio Oncology Therapeutics, Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BridgeBio Oncology Therapeutics, Inc.

How large is the market capitalisation of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
The market capitalisation of BridgeBio Oncology Therapeutics, Inc. is $189M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
Earnings per share at BridgeBio Oncology Therapeutics, Inc. are $0.53 (price ÷ EPS = P/E 3.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
The return on equity (ROE) of BridgeBio Oncology Therapeutics, Inc. is −46.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
On an EBIT basis the return on assets of BridgeBio Oncology Therapeutics, Inc. is −3,913% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does BridgeBio Oncology Therapeutics, Inc. (BBOT) generate?
The free cash flow of BridgeBio Oncology Therapeutics, Inc. is −$115M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BridgeBio Oncology Therapeutics, Inc. (BBOT) hold?
BridgeBio Oncology Therapeutics, Inc. holds more cash than debt, $371M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BridgeBio Oncology Therapeutics, Inc. in the live analysis

One click puts BridgeBio Oncology Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.